Table 2.
Previous and concomitant therapies [n (%)]
| Previous | Week 0 | Week 14 | Week 54 | |
|---|---|---|---|---|
| 5-asa | 95 (99) | 59 (61.5) | 61 (67) | 50 (69.4) |
| Steroids | 91 (94.8) | 62 (64.6) | 31 (34.1) | 5 (6.9) |
| Thiopurines | 57 (59.4) | 18 (18.8) | 15 (16.5) | 10 (13.9) |
| anti-TNF | 37 (38.5) | |||
| Infliximab | 27 (28.1) | |||
| Adalimumab | 10 (10.4 | |||
| Golimumab | 11 (11.5) |
Percentages refer to 96 patients for previous treatments and week 0, 91 patients for week 14, and 72 patients for week 54